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Glucagon-like peptide 1 (GLP-1) is a growth factor. GLP-1 mimetics are on the 
market as treatments for type 2 diabetes and are well tolerated. These drugs have 
shown neuroprotective properties in animal models of neurodegenerative disorders. In 
addition, the GLP-1 mimetic exendin-4 has shown protective effects in animal models 
of Parkinson’s disease (PD), and a clinical trial in PD patients showed promising first 
results. Liraglutide and lixisenatide are two newer GLP-1 mimetics which have a 
longer biological half-life than exendin-4. We previously showed that these drugs 
have neuroprotective properties in an animal model of Alzheimer’s disease. Here we 
demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) mouse model of PD. MPTP was injected once-daily 
(20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p.. When 
comparing exendin-4 (10nmol/kg), liraglutide (25nmol/kg) and lixisenatide 
(10nmol/kg), it was found that exendin-4 showed no protective effects at the dose 
chosen. Both liraglutide and lixisenatide showed effects in preventing the MPTP- 
induced motor impairment (Rotarod, open field locomotion, catalepsy test), reduction 
in Tyrosine Hydroxylase (TH) levels (dopamine synthesis) in the substantia nigra and 
basal ganglia, a reduction of the pro-apoptotic signaling molecule BAX and an 
increase in the anti-apoptotic signaling molecule Bcl-2. The results demonstrate that 
in this study, both liraglutide and lixisenatide are superior to exendin-4, and both 
drugs show promise as a novel treatment of PD. 
 
 





Parkinson’s disease (PD) is a chronic neurodegenerative disorder of motor control, 
characterised by a progressive loss of dopaminergic neurons in the substantia nigra 
pars compacta (SNpc) and the degeneration of projection axons and dopaminergic 
synapses to the striatum, which leads to tremors, muscular rigidity, bradykinesia, and 
postural and gait abnormalities (Langston, 2002). There is currently no treatment for 
this condition. Recently, the neuroprotective and restorative effect of growth factors 
such as glia-derived neurotrophic factor (GDNF) in cell culture and animal models of 
Parkinson’s disease has drawn attention to the potential of using growth factors as a 
treatment (Mickiewicz and Kordower, 2011). One major stumbling block for this 
strategy is the fact GDNF and other growth factors do not cross the blood-brain 
barrier (BBB) (Holscher, 2014b). The growth factor glucagon-like protein 1 (GLP-1) 
and its analogues have shown neuroprotective effects in several disease models of 
neurodegeneration (Perry and Greig, 2004, Holscher, 2013). Several GLP-1 receptor 
agonists have been developed as treatments for type 2 diabetes, and some of these can 
cross the BBB (Kastin et al., 2002, Kastin and Akerstrom, 2003, McClean et al., 2011, 
Hunter and Holscher, 2012). Previous investigations found that the GLP-1 receptor 
agonist exendin-4 showed good neuroprotective effects in animal models of PD 
(Bertilsson et al., 2008, Harkavyi et al., 2008, Kim et al., 2009, Li et al., 2009). 
Exendin-4 also had been tested in a pilot clinical trial in people with PD and showed 
encouraging effects (Aviles-Olmos et al., 2013, Aviles-Olmos et al., 2014). Exendin-4 
is superior to endogenous GLP-1 as it is resistant to cleavage by the protease DPP-IV 
and has a much enhanced biological half-life in the blood (Baggio and Drucker, 
2007). Newer GLP-1 mimetics have been developed since, and they have longer 
survival times in the blood stream (Tan and Bloom, 2013). Liraglutide is an acetylated 
form of the GLP-1 peptide that has a much enhanced half-life and that is on the 
market as a drug treatment for diabetes (Victoza) (Raun et al., 2007). Lixisenatide 
also is a novel GLP-1 mimetic that recently has been approved in Europe as a 
treatment for diabetes (Lyxumia) (Elkinson and Keating, 2013). Both drugs have 
shown neuroprotective effects in animal models of Alzheimer’s disease (McClean et 
al., 2011, McClean and Holscher, 2014b). We therefore tested the effects of exendin-
4, liraglutide and lixisenatide in the MPTP mouse model of PD at doses that showed 
effect in previous in vivo studies for comparison. MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine is a neurotoxin precursor to MPP+, which induces classic 
symptoms of Parkinson's disease by impairing or destroying dopaminergic neurons in 
the substantia nigra (Nakamura and Vincent, 1986, Gerlach et al., 1991). MPTP is a 
widely used chemical to induce a Parkinson-like state in animals (Nakamura and 





2. Materials and methods 
 
2.1 Animals 
C57Bl6 male mice, 8 weeks old, 25-30g in weight were randomly divided into 8 
groups: (1) control group, (2) MPTP/vehicle group (3) exendin-4 group  (4) 
MPTP/exendin-4 group,  (5) liraglutide group, (6) MPTP/liraglutide group, (7) 
lixisenatide group, (8) MPTP/Lixisenatide group. N=12 animals per group). Mice 
received 20 mg/kg/day MPTP in normal saline intraperitoneally for 7 consecutive 
days. Drugs dissolved in saline were administered after each MPTP injection. After 
the 7 days, mice received a further 7 days of drug or saline injection once-daily (Fig. 
1). Drug concentrations were exendin-4: 10nmol/kg i.p., lixisenatide: 10nmol/kg i.p., 
liraglutide: 25nmol/kg i.p.. Animals were handled for one week and exposed to the 
experimental room and the apparatus 2-3 times before commencement of 
experiments. All experiments were licenced by the UK Home Office (PPL 70 8236). 
 
2.2 Peptides and chemicals 
The peptides were synthetised by ChinaPeptides Co., Ltd (Shanghai, China) to 95% 
purity. The purity of the peptide was confirmed by reversed-phase HPLC and 
characterised using matrix assisted laser desorption/ionisation time of flight (MALDI-
TOF) mass spectrometry. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 
paraformaldehyde (PFA) was purchased from Sigma-Aldrich (St Louis, MO, USA). 
Rabbit anti- tyrosine hydroxylase (TH), Bcl-2, BAX, Goat Anti-rabbit IgG H&L 
(HRP) secondary antibody were obtained from Abcam (Cambridge, UK). The 
Bicinchoninic acid (BCA) protein assay kit was purchased from Applygen 
Technologies Inc. (Beijing, China). Sodium chloride, ethylene glycol, and 3,3-
diaminobenzidine (DAB) were purchased from ZSGB-BIO Co. (Beijing, China).  
The transfer polyvinylidene difluoride membranes and Amersham ECL Prime 
western blotting detection reagent were purchased from GE Life Sciences (USA).  
 
2.3 Open field motor activity test 
The open field is a square box (45cm×45cm) with 40cm high walls that prevent 
escape. The floor is marked with a grid of lines (separated by 9cm), The mice were 
individually placed in one corner of the open field. The number of crossed lines 
during 10min of testing session was recorded as the total distance. Animals were 
tracked by a computerised video system that measured path length (Biosignals, USA). 
 
2.4 Rotarod 
Mice were placed on a Rotarod system (II-755, IITC Life Science, USA) that 
accelerated from 5 to 20 rpm over a period of 50s. The length of time that each animal 
was able to stay on the rod was recorded as the latency to fall, registered 
automatically by a trip switch under the floor of each rotating drum. A maximum trial 
length of 180s was given. 
 
2.5 Catalepsy Bar test 
Catalepsy was evaluated in the bar test immediately after MPTP drug treatment and 
on every second day after the drug treatment. The frame was made of wood (25 cm 
long; 5 cm wide, 10 cm high) with a horizontal bar (0.8 cm diameter, 20 cm long) 
suspended 30 cm above the floor. Catalepsy was evaluated by measuring the mean 
time taken for a mouse to climb over the bar after being laid across it with its hind 
limbs on the floor.  
 
2.6 Histology 
After the experiments, animals were perfused transcardially with PBS buffer followed 
by ice-cold 4% paraformaldehyde in PBS. Brains were removed and fixed in 4% 
paraformaldehyde for at least 24h before being transferred to 30% sucrose solution 
overnight. Brains were then snap frozen and coronal sections of 30-micron thickness 
were cut at a Leica cryostat. Sections were taken for the basal ganglia from Bregma 1.54mm to Bregma -0.34mm and for Substantia nigra from -2.46mm to Bregma -3.88mm 
Sections were chosen according to stereological rules (Bondolfi et al., 2002) with the 
first section taken at random and every 3th section afterwards. Between 3 and 6 
sections were analysed per brain. The sections were analysed on an Axio Scope 1 
(Zeiss, Germany) and photographed with a digital camera (AxioCam). A dissector 
was applied to the images in random orientation to avoid sampling bias (Bondolfi et 
al., 2002). In the SN, TH positive cells were counted per dissector. In the other 
immunohistological assessments, the greyscale (optical density) of stained area per 
dissector was analysed using the image analysis programme Image J 1.41o with the 
Multi threshold plug (NIH, USA) (http://rsb.info.nih.gov/ij) (McClean et al., 2011). 
The scale of staining correlates with the stained antigen. 
 
2.7 Western blot 
Brains were snap frozen at -20 degrees. Striatum tissue containing 5 µg of protein was 
separated on 4–12% gradient Bis-Tris gel with molecular marker and electrophoresed 
in running buffer at 200 mV for 40 min followed by transfer to the transfer 
membrane. Following protein transfer, the membrane was washed in 1X TBST (tris-
buffered saline with 0.05% Tween-20, pH 8) and blocked in 5% skimmed milk for 1 
h. The membrane was then incubated with anti-Bax (1 : 200), anti-Bcl-2 (1 : 200), and 
anti-ß-actin (1:400) antibodies for 1 h and after three washes in PBS further incubated 
with 1 : 400 horseradish peroxidase-conjugated antirabbit IgG. The protein bands 
were visualized by Amersham ECL Prime western blotting detection reagent 
according to the manufacturer’s recommendation. Bands were analysed using a. 
image analysis system (BioRad, USA). Bands were normalised for loading control. 
Each run was repeated three times. 
 
2.8 Statistics 
Data were analysed using the program Prism (Graphpad software Inc., USA), results 
are expressed as means ± SEM. Data were analyzed by 1-way or 2-way ANOVA, 





3.1 Rotarod motorsensory performance 
 
The injection of MPTP impaired the ability of mice to stay on the rotating rod for 3 
min. In a two-way ANOVA, an overall difference was found between groups 
(p<0.0001 drug, interaction ns., time ns.). In subsequent two-way ANOVAs, a 
difference was found between groups injected with saline or drugs and groups 
injected with MPTP (p<0.0001 drug, interaction ns., time ns.). Furthermore, a 
difference was found between MPTP + Lira / MPTP + Lixi and the groups MPTP + 
saline / MPTP + exendin-4 (p<0.0001 drug, interaction ns., time ns.). The drugs 
liraglutide and lixisenatide were able to reverse some of the impairments of MPTP 
while exendin-4 was not. N=12 per group, fig. 2. 
 
3.2 Open field distance traveled 
 
The injection of MPTP reduced the spontaneous locomotion of mice and the overall 
time traveled in 10 min. In a two-way ANOVA, an overall difference was found 
between groups (p<0.0001 drug, interaction ns., time ns). In subsequent two-way 
ANOVAs, a difference was found between groups injected with saline or drugs and 
groups injected with MPTP (p<0.0001 drug, interaction ns., time ns.). Furthermore, a 
difference was found between MPTP + Lira / MPTP + Lixi and the groups MPTP + 
saline / MPTP + exendin-4 (p<0.0001 drug, interaction ns., time p<0.001). The drugs 
liraglutide and lixisenatide were able to reverse some of the impairments of MPTP 
while exendin-4 was not. The improvement / reversal of the symptoms induced by 
liraglutide and lixisenatide was dependent on time, fig. 3. 
 
3.4 Catalepsy test 
 
The injection of MPTP induced catalepsy in mice. In a two-way ANOVA, an overall 
difference was found between groups (p<0.0001 drug, interaction ns., time ns.). In 
subsequent two-way ANOVAs, a difference was found between groups injected with 
saline or drugs and groups injected with MPTP (p<0.0001 drug, interaction ns., time 
ns.). Furthermore, a difference was found between MPTP + Lira / MPTP + Lixi and 
the groups MPTP + saline / MPTP + exendin-4 (p<0.0001 drug, interaction ns., time 
ns.). The drugs liraglutide and lixisenatide were able to reverse some of the 
impairments of MPTP while exendin-4 was not. N=12 per group, fig. 4. 
 
3.5 TH positive neurons in the substantia nigra, pc. 
 
In the histological analysis of the dopamine biomarker tyrosine hydroxilase in the SN, 
MPTP reduced the numbers of TH positive cells significantly. In a one-way ANOVA 
with Bonferroni post-hoc test, MPTP + saline and MPTP+exendin-4 groups showed 
fewer TH- positive neurons in the SN than drug treated mice (p<0.001; n=6 per 
group). MPTP treated mice injected with Lixisenatide or liraglutide showed no 
difference to non-lesioned mice, fig. 5. 
 
3.6 Tyrosine hydroxylase relative expression levels in the striatum. 
 
In the histological analysis of relative TH expression levels in the striatum, MPTP 
reduced the expression levels of TH significantly. In a one-way ANOVA with 
Bonferroni post-hoc test, MPTP + saline and MPTP+exendin-4 groups showed fewer 
TH- positive neurons in the SN than drug treated mice (p<0.001). Mice treated with 
MPTP and injected with liraglutide or lixisenatide showed reduced TH levels 
compared to non-lesioned mice (p<0.01). Mice treated with MPTP and injected with 
liraglutide or lixisenatide showed higher TH levels compared to MPTP + saline or 
MPTP + exendin-4 (p<0.05); n=6 per group, fig. 6. 
 
3.7 Expression levels of BAX and Bcl-2 in the striatum 
 
MPTP reduced expression levels in the striatum of the anti-apoptotic signaling 
peptide B-cell lymphoma -2 (Bcl-2) in western blot quantifications (one-way ANOVA 
with Bonferroni post hoc test, p<0.001). Injection of liraglutide or lixisenatide 
enhanced the expression after MPTP treatment compared to controls (p<0.05). MPTP 
+ Exendin-4 showed no enhancement compared to MPTP only. Injection of liraglutide 
or lixisenatide enhanced the expression after MPTP treatment compared to MPTP + 
Exendin-4  (p<0.05). MPTP enhanced expression levels in the striatum of the 
apoptotic signaling peptide BAX (one-way ANOVA with Bonferroni post hoc test, 
p<0.001). Injection of exendin-4, liraglutide or lixisenatide reduced the expression 
after MPTP treatment compared to controls (p<0.05). N=4, fig. 7. 
 
 
 4. Discussion 
 
The results demonstrate for the first time that that the novel GLP-1 mimetics 
liraglutide and lixisenatide have protective effects in a PD mouse model. Both drugs 
are superior to the older drug exendin-4 in protecting mice from the toxic effects of 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP is a neurotoxin precursor 
to MPP+, which causes symptoms of Parkinson's disease by damaging or destroying 
dopaminergic neurons in the substantia nigra (Nakamura and Vincent, 1986, Gerlach 
et al., 1991). MPTP is lipophilic and can cross the blood–brain barrier. There, MPTP 
is metabolised into the toxic cation 1-methyl-4-phenylpyridinium (MPP+) by the 
monoamine oxidase B (Glover et al., 1986). MPP+ kills primarily dopamine-
producing neurons in the substantia nigra, pars compacta (Nakamura and Vincent, 
1986). MPP+ interferes with complex 1 of the mitochondrial electron transport chain, 
which leads to the production of free radicals and eventually to neuronal death 
(Kinemuchi et al., 1987, Smith and Bennett, 1997). MPTP is a widely used chemical 
to induce a Parkinson-like state in animals (Nakamura and Vincent, 1986, Kopin and 
Markey, 1988). 
In the present study, MPTP induced Parkinson-like motor impairments, reduced the 
expression of the dopamine- synthetising enzyme tyrosine hydroxilase (TH) in the 
substantia nigra pars compacta and also in the striatum. Furthermore, expression of 
the anti-apoptotic protein Bcl-2 were much reduced by MPTP, and levels of the pro-
apoptotic signaling molecule BAX were enhanced. While the MPTP model of PD 
does not recapitulate all aspects and symptoms of PD, it is an acceptable chemically 
induced model for drug testing (Kinemuchi et al., 1987, Kopin and Markey, 1988). 
In our study, the older GLP-1 mimetic exendin-4 did not protect mice from the MPTP 
induced effects. This result is surprising, as two previous studies showed good 
protection of MPTP treated mice using exendin-4 (Kim et al., 2009, Li et al., 2009). 
However, the exact conditions of the experiments are different, suggesting that under 
the conditions chosen in our study, exendin-4 could not protect neurons. In the study 
by Li et al. (2009), exendin-4 was injected directly into the brain via an Alzet pump, 
and the C57B/l6 mice received only 4 MPTP doses (20mg/kg i.p.). In the study of 
Kim et al. (2009) using C57B/l6 mice, only 4 MPTP injections were made with 
exendin-4 injections 30 min previously (10mg/kg i.p.). Our study treated the mice 7 
times over 7 days with MPTP (20mg/kg i.p.). Therefor, it is feasible that exendin-4 is 
not potent enough to protect neurons using this dose of MPTP.  
Exendin-4 has shown neuroprotective effects in other animal models of PD that use 
different chemicals to induce PD like symptoms, 6-OHDA or LPS injection into the 
brain (Bertilsson et al., 2008, Harkavyi et al., 2008). More importantly, a pilot study 
in patients with PD demonstrated encouraging protective effects (Aviles-Olmos et al., 
2013, Aviles-Olmos et al., 2014). A phase II clinical study testing Bydureon, the once-
weekly formulation of exendin-4 is currently ongoing. Therefore, we can assume that 
exendin-4 does have some neuroprotective effects in PD, even if this was not visible 
in our study. 
Interestingly, the two newer GLP-1 receptor agonists liraglutide and lixisenatide 
showed good protective effects in the present study. Both drugs have never been 
tested in animal models of PD before, so this study presents the novel findings that 
they are superior to exendin-4 and are neuroprotective from the effects of MPTP in 
the conditions chosen in our study. As all three drugs are currently on the market as 
treatments for type 2 diabetes (Campbell and Drucker, 2013, Elkinson and Keating, 
2013), it is possible to fast-track these into clinical trials in PD. Both liraglutide and 
lixisenatide are newer drug developments and are suprior to exendin-4 in terms of 
biological half-life in the body and efficacy in treating diabetes (Lovshin and Drucker, 
2009, Campbell and Drucker, 2013). Both drugs also show good neuroprotective 
effects in animal models of Alzheimer disease (McClean and Holscher, 2014a, b). 
Two clinical trial testing exendin-4 or liraglutide in Alzheimer patients are currently 
ongoing (for a summary, see (Holscher, 2014a). Liraglutide also showed good 
neuroprotective effects in an animal model of stroke (Sato et al., 2013, Briyal et al., 
2014) and head trauma (DellaValle et al., 2014, Hakon et al., 2015). 
The basis for the neuroprotective effects of GLP-1 receptor activation are most likely 
based on the growth-factor like activity of GLP-1. GLP-1 activates the GLP-1 
receptor that is coupled to a growth factor related second messenger signaling cascade 
such as MAPk2 and PKA and reduces apoptosis signaling (Sharma et al., 2013) and 
also enhances the release of other growth factors such as BDNF and NGF in the brain  
(DellaValle et al., 2014, Ohtake et al., 2014). 
Since exendin-4 showed first promising neuroprotective effects in a pilot study in PD 
patients, newer GLP-1 mimetics such as liraglutide and lixisenatide may be more 
effective in treating PD patients. The results of the present study support the proposal 
of testing of liraglutide and lixisenatide in clinical trials in PD as they promise better 
neuroprotection in this disease. Further tests of these drugs in different animal models 
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Study design and timelines. 
 
 
Fig. 2: Rotarod sensorymotor performance 
Latencies of mice to stay on the rotating rod for 3 min. N=12 per group. One-way 
ANOVA with subsequent post hoc tests. *=p<0.05; ***=p<0.001. 
 
Fig. 3: Open field locomotion test 
The injection of MPTP reduce the spontaneous locomotion of mice and the overall 
time traveled in 10 min. A difference was found between groups injected with saline 
or drugs and groups injected with MPTP (p<0.0001; two-way ANOVA). Furthermore, 
a difference was found between MPTP + Lira / MPTP + Lixi and the groups MPTP + 
saline / MPTP + exendin-4 (p<0.0001).  
 
Fig. 4: Catalepsy test 
The injection of MPTP induced catalepsy in mice. A difference was found between 
groups injected with saline or drugs and groups injected with MPTP (p<0.0001). 
Furthermore, a difference was found between MPTP + Lira / MPTP + Lixi and the 
groups MPTP + saline / MPTP + exendin-4 (p<0.0001). The drugs liraglutide and 
lixisenatide were able to reverse some of the impairments of MPTP while exendin-4 
was not. N=12 per group. 
 
Fig. 5: TH positive neurons in the substantia nigra, pc. 
In a one-way ANOVA with Bonferroni post-hoc test, numbers of TH positive cells 
were compared (***=p<0.001; n=6 per group). Scale bar 100µm.  
 
Fig. 6: Relative expression of TH in the striatum. 
One-way ANOVA with post hoc test, (*=p<0.05; **=p<0.01; ***=p<0.001, n=6 per 
group). Scale bar 1mm. 
 
Fig. 7: Expression levels of BAX and Bcl-2 in the striatum 
MPTP reduced expression levels in the striatum of the anti-apoptotic signaling 
peptide B-cell lymphoma -2 (Bcl-2) in western blot quantifications (one-way ANOVA 
with Bonferroni post hoc test, *=p<0.05; ***=p<0.001). N=4 per group. 
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